Pregnancies Sample Clauses

Pregnancies. The City will accommodate requests for transfer from pregnant employees whose job duties require frequent exposures to video display equipment subject to the following: 56.5.2.1 such transfer will be limited to other positions which are vacant which the transferee is qualified to perform: 56.5.2.2 to voluntary trading of positions where both parties are competent to perform the new assignments: 56.5.2.3 to any position held by a temporary employee if the pregnant employee is qualified.

Pregnancies. In the event an officer discovers that she is pregnant, the following conditions will apply: 1. As soon as the officer verifies that she is pregnant, she will complete an Illness/Injury/Incident Report. The form must be accompanied by a note from her personal physician that will include the estimated due date, as well as any other information the doctor deems necessary for the Department to have, in order to make decisions about any potential limitations. 2. Upon receipt of the Illness/Injury/Incident Report, the Commander, Support Services Division, will forward a copy of the pregnant officer's job description to the physician for his or her review, in order to determine a date beyond which the officer will not be able to perform all her duties as a sworn police officer. The Commander, Support Services Division, will then relay that information to the commander of the officer who will make a determination as to the officer's current and future duty status (including the wearing of the uniform) throughout the course of the pregnancy.

Pregnancies. 16.1. The Tenant accepts the fact that the Landlord and/or any of its employees are not equipped to attend to any emergency medical emergencies or general medical treatment more so in respect to pregnancies. 16.2. The Tenant hereby agrees that within the 7th moth of such pregnancy the Tenant shall vacate Leased Premises. 16.3. The provisions of paragraph 14.1.2 and 14.1.3 shall apply mero motu to this paragraph.

Pregnancies. To ensure patient safety, each pregnancy in a patient on study treatment must be reported to the Sponsor within 24 hours of learning of its occurrence. The pregnancy must be followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. Pregnancy should be recorded on a Clinical Study Pregnancy Form and reported by the investigator to the Sponsor. Pregnancy follow-up should be recorded on the same form and must include an assessment of the possible relationship to the study treatment of any pregnancy outcome. Any SAE experienced during pregnancy must be reported on the SAE Report Form. Pregnancy outcomes must be collected for the female partners of any males who took study treatment in this study. Consent to report information regarding these pregnancy outcomes should be obtained from the mother.

Pregnancies. Reporting of pregnancies will be as for AE's (see Section 6.5.2).

Pregnancies. Simcere shall notify ▇▇▇▇▇ within 24 hours of becoming aware of any patients who become pregnant while being treated with the Licensed Product, or within 28 days of the last dose of the Licensed Product. Simcere will reasonably cooperate with ▇▇▇▇▇ to monitor the course and outcome of such pregnancies, and to resolve any queries from Regulatory Authorities.

Pregnancies. The Authority will accommodate requests for transfer from pregnant employees whose job duties require frequent exposures to video display equipment subject to the following: 52.3.2.1 such transfer will be limited to other positions which are vacant which the transferee is qualified to perform: 52.3.2.2 to voluntary trading of positions where both parties are competent to perform the new assignments: 52.3.2.3 to any position held by a temporary employee if the pregnant employee is qualified.

Pregnancies. Studies with levosimendan have not been performed in pregnant women. Subjects of childbearing potential should use effective contraception with their partners during the period of study treatment. A female subject must be instructed that, if she becomes pregnant during the study, she must immediately inform the investigator. Pregnancies occurring up to 90 days after discontinuation of levosimendan also must be reported to the investigator. The subject should be advised of the risks of continuing the pregnancy and the possible teratogenic effects of levosimendan. The investigator should report all pregnancies to the sponsor within 24 hours of becoming aware of the pregnancy. Within 24 hours of learning of the pregnancy, the investigator should complete a Serious Adverse Event Report eCRF. Monitoring of the subject should continue until conclusion of the pregnancy. The investigator will complete eCRFs to provide the sponsor with information concerning the subject’s pregnancy and information after birth. Pregnancy occurring in the partner of a male subject participating in the study similarly should be reported to the investigator and the sponsor. The partner should be counseled and followed as described above.